KEY TAKEAWAYS
- The PEACE is an observational study aimed to assess the feasibility of collecting data on patient satisfaction towards EOL for gynecological cancer pts.
- The study will use the CANHELP-Lite, FACIT, CANHELP lite bereavement, and Quality of Death and Dying questionnaires to assess patient and carer satisfaction with care.
- A sample size of 73 pts is needed to rule out a 60% completion rate in favor of a 75% rate with 80% power and 95% confidence, assuming a 10% dropout rate.
Many women with advanced gynecological cancer receive chemotherapy in the last 30 days of life, even though chemotherapy may not be effective and could have negative side effects. Researchers aimed to assess the feasibility of collecting data on patient satisfaction towards the end of life (EOL) for gynecological cancer pts.
The study will enroll advanced gynecological cancer pts (4-month life expectancy, on/off treatment), capable (both physically and cognitively) of independent outcome measures, with an optional caregiver. The study will use the CANHELP-Lite (Canadian Health Care Evaluation Project) and FACIT(Functional Assessment of Chronic Illness Therapy) instruments to gauge patient and carer satisfaction and assess the significance of care aspects. They will employ the CANHELP Lite bereavement and Quality of Death and Dying questionnaire to evaluate carer perceptions during bereavement and the quality of the patient’s passing.
The study will gather data on EOL treatment. Patient and carer satisfaction and the quality of the dying process will be summarized using standard descriptive statistics. A sample size of 73 pts is needed to rule out a 60% completion rate in favor of a 75% rate with 80% power and 95% confidence, assuming a 10% drop-out rate; enrollment started in December 2022 for this study.
Source: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.TPS5635
Clinical Trial: https://clinicaltrials.gov/study/NCT05142150
Kristina Lindemann, Heidi Liland, Mia Sejer Donner, Sue Brew, Yeh Chen Lee, Ingvild Vistad, Elisabeth Berge Nilsen, Janine Margaret Lombard, Mansoor Raza Mirza, Kristine Madsen, Anne Marie Hansson, John Andrews, Rachel Campbell, and Alison J. Davis. DOI: 10.1200/JCO.2023.41.16_suppl.TPS5635 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) TPS5635-TPS5635.
